BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
361.65
+3.58 (1.00%)
At close: Oct 5, 2026, 4:00 PM EDT
364.67
+3.02 (0.84%)
Pre-market: Oct 6, 2026, 5:40 AM EDT
BeOne Medicines AG Revenue
BeOne Medicines AG had revenue of $1.71B in the quarter ending June 30, 2026, with 29.63% growth. This brings the company's revenue in the last twelve months to $6.13B, up 34.35% year-over-year. In the year 2025, BeOne Medicines AG had annual revenue of $5.34B with 40.23% growth.
Revenue (ttm)
$6.13B
Revenue Growth
+34.35%
P/S Ratio
6.71
Revenue / Employee
$510,747
Employees
12,000
Market Cap
41.12B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.34B | 1.53B | 40.23% |
| Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
| Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
| Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
| Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
| Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
| Dec 31, 2019 | 428.21M | 229.99M | 116.03% |
| Dec 31, 2018 | 198.22M | -40.17M | -16.85% |
| Dec 31, 2017 | 238.39M | 237.32M | 22,179.16% |
| Dec 31, 2016 | 1.07M | -7.75M | -87.86% |
| Dec 31, 2015 | 8.82M | -4.22M | -32.37% |
| Dec 31, 2014 | 13.04M | 1.89M | 16.93% |
| Dec 31, 2013 | 11.15M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Regeneron Pharmaceuticals | 15.53B |
| Incyte | 5.82B |
| argenx SE | 5.32B |
| Alnylam Pharmaceuticals | 4.80B |
| Genmab | 4.13B |
| BioNTech SE | 3.03B |
| Royalty Pharma | 2.54B |
| Moderna | 2.23B |
ONC News
- 3 days ago - BeOne Medicines Ltd (ONC) Insider Sale: SVP, General Counsel Chan Lee Sells 1,115 Shares - GuruFocus
- 4 days ago - Biotech Leader BeOne Medicines Poised To Hit Early Buy Points - Investor's Business Daily
- 4 days ago - BeOne Medicines price target raised to $445 from $425 at JPMorgan - TheFly
- 14 days ago - BAKER BROS. ADVISORS LP Boosts BeOne Medicines Ltd (ONC) Stake -- Shares Look 5% Undervalued on ... - GuruFocus
- 21 days ago - BeOne Medicines AG at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
- 21 days ago - BeOne Medicines AG Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 26 days ago - BeOne Medicines price target raised to $415 from $407 at Barclays - TheFly
- 5 weeks ago - BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference - Business Wire